LB80380

DRUG2 trials

Sponsors

LG Life Sciences

Conditions

Chronic Hepatitis B

Phase 1

Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

CompletedNCT00895596

LG Life SciencesChronic Hepatitis B

Start: 2004-03-31End: 2007-12-31Updated: 2009-05-08

Phase 2

Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

LG Life SciencesChronic Hepatitis B

Start: 2010-08-31End: 2012-09-30Target: 115Updated: 2012-04-16